ABOS
Acumen Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-36/100
Last price
2.03
▼ 0.10 (4.69%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.13
Day high
2.14
Day low
2.00
Volume
562.87K
Market cap
$146.80M
P/E (TTM)
—
52W range
1.50 – 3.60
Trailing performance
Returnvs SPY
1W
-9.58%
-11.5%
1M
-36.16%
-37.3%
3M
-25.64%
-30.2%
6M
-22.81%
-41.0%
YTD
-3.79%
-18.0%
1Y
+17.34%
+0.9%
3Y
-51.08%
-133.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ABOS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+264.80K
Net buying
Buy transactions
9
303.50K shares
Sell transactions
2
38.70K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
4.91M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 17, 26 | PORTER DERRELL P Director |
SELL | 32.30K | $75.24K | Direct |
| Jun 17, 26 | PORTER DERRELL P Director |
CONVERSION | 19.50K | $20.86K | Direct |
| Jun 9, 26 | FOUNTAIN NATHAN B Director |
SELL | 6.40K | $14.27K | Direct |
| Jun 3, 26 | DRAPKIN KIMBERLEE COBLEIGH CPA Director |
STOCK | 35.50K | $0 | Direct |
| Jun 3, 26 | GOLUMBESKI GEORGE S Director |
STOCK | 35.50K | $0 | Direct |
| Jun 3, 26 | IVES JEFFREY L Director |
STOCK | 35.50K | $0 | Direct |
| Jun 3, 26 | PORTER DERRELL P Director |
STOCK | 35.50K | $0 | Direct |
| Jun 3, 26 | STALFORT JOHN A Director |
STOCK | 35.50K | $0 | Direct |
| Jun 3, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
STOCK | 35.50K | $0 | Indirect |
| Jun 3, 26 | FOUNTAIN NATHAN B Director |
STOCK | 35.50K | $0 | Direct |
| Jun 3, 26 | STOPPEL LAURA Director |
STOCK | 35.50K | $0 | Direct |
| Mar 16, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
STOCK | 6.06M | $20.00M | Indirect |
| Mar 6, 26 | MEISNER DEREK M Officer |
SELL | 2.09K | $6.81K | Direct |
| Mar 6, 26 | MEISNER DEREK M Officer |
CONVERSION | 2.09K | $3.87K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARTON RUSSELL |
Chief Operating Officer | 205.09K | Sale |
DOHERTY JAMES J |
President | 220.90K | Stock Award(Grant) |
MEISNER DEREK M |
Officer | 174.00K | Sale |
O'CONNELL DANIEL JOSEPH |
Chief Executive Officer | 881.27K | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
SCHACTERLE AMY PH.D. |
Officer | 92.30K | Stock Award(Grant) |
SIEMERS ERIC M.D. |
Officer | 255.37K | Sale |
STALFORT JOHN A |
Director | 220.62K | Stock Award(Grant) |
STOPPEL LAURA |
Director | 48.30K | Stock Award(Grant) |
WILLIAM MATTHEW ZUGA |
Chief Financial Officer | 304.92K | Sale |
Fundamentals
Market cap$146.80M
Enterprise value$68.25M
Revenue (TTM)—
Gross profit$-86.79M
EBITDA$-105.37M
Net income$-105.04M
EPS (TTM)$-1.56
Free cash flow$-56.50M
Total cash$110.20M
Total debt$31.65M
Book value / share$0.79
Shares outstanding72.32M
Float37.05M
Short % of float5.56%
Dividend yield0.00%
Beta (5Y)0.33
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.42
PEG ratio—
Price / sales—
Price / book2.56
EV / revenue—
EV / EBITDA-0.65
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-120.50%
Return on assets-45.77%
Debt / equity55.26
Current ratio2.47
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $104.89M | $93.80M | $42.32M | $32.36M | +11.8% |
| Selling, general & admin | $18.95M | $20.22M | $18.82M | $12.88M | -6.3% |
| Total operating expense | $123.83M | $114.02M | $61.14M | $45.24M | +8.6% |
| Operating income | -$123.83M | -$114.02M | -$61.14M | -$45.24M | -8.6% |
| Net interest income | $3.22M | $10.25M | $10.21M | $2.39M | -68.6% |
| Pre-tax income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -18.6% |
| Net income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -18.6% |
| Net income to common | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -18.6% |
| Basic EPS | -2.00 | -1.71 | -1.08 | -1.06 | -17.0% |
| Diluted EPS | -2.00 | -1.71 | -1.08 | -1.06 | -17.0% |
| EBIT | -$117.11M | -$98.26M | -$51.79M | -$42.86M | -19.2% |
| EBITDA | -$116.93M | -$98.08M | -$51.61M | -$42.69M | -19.2% |
| Basic shares | 60.56M | 60.01M | 48.61M | 40.60M | +0.9% |
| Diluted shares | 60.56M | 60.01M | 48.61M | 40.60M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $53.99M | $35.63M | $66.89M | $130.10M | +51.5% |
| Cash & short-term investments | $116.86M | $171.56M | $243.52M | $177.60M | -31.9% |
| Total current assets | $122.25M | $178.31M | $246.62M | $180.33M | -31.4% |
| Property, plant & equipment | $243.00K | $339.00K | $503.00K | $270.00K | -28.3% |
| Goodwill & intangibles | $29.00K | $75.00K | $169.00K | — | -61.3% |
| Total assets | $122.83M | $238.99M | $310.13M | $196.59M | -48.6% |
| Total current liabilities | $30.01M | $27.61M | $12.97M | $7.81M | +8.7% |
| Current debt | $8.77M | — | — | — | — |
| Long-term debt | $22.40M | $28.45M | $27.34M | — | -21.3% |
| Total debt | $31.31M | $28.73M | $28.49M | $105.00K | +9.0% |
| Total liabilities | $52.40M | $57.18M | $43.15M | $7.81M | -8.3% |
| Retained earnings | -$446.46M | -$325.13M | -$222.80M | -$170.43M | -37.3% |
| Shareholder equity | $70.43M | $181.82M | $266.97M | $188.78M | -61.3% |
| Working capital | $92.25M | $150.70M | $233.64M | $172.52M | -38.8% |
| Net tangible assets | $70.40M | $181.74M | $266.80M | $188.78M | -61.3% |
| Shares issued | 60.58M | 60.09M | 57.91M | 41.03M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -18.6% |
| Depreciation & amortisation | $184.00K | $178.00K | $184.00K | $169.00K | +3.4% |
| Stock-based compensation | $9.85M | $9.63M | $6.14M | $3.06M | +2.3% |
| Change in working capital | -$5.12M | $11.65M | $3.87M | $3.99M | -143.9% |
| Operating cash flow | -$115.54M | -$86.22M | -$43.06M | -$35.15M | -34.0% |
| Capital expenditure | -$88.00K | -$16.00K | -$21.00K | -$161.00K | -450.0% |
| Investing cash flow | $133.93M | $48.03M | -$171.67M | $39.19M | +178.9% |
| Share buybacks | -$73.00K | -$41.00K | $0 | — | -78.0% |
| Dividends paid | — | $0 | $0 | — | — |
| Financing cash flow | -$34.00K | $6.93M | $151.75M | $3.91M | -100.5% |
| Free cash flow | -$115.63M | -$86.23M | -$43.09M | -$35.31M | -34.1% |
| End cash position | $54.22M | $35.86M | $67.12M | $130.10M | +51.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $27.81M | $16.48M | $20.53M | $21.97M | $37.13M | — | +68.7% |
| Selling, general & admin | $4.75M | $4.67M | $4.67M | $4.54M | $4.63M | — | +1.8% |
| Total operating expense | $32.56M | $21.15M | $25.20M | $26.51M | $41.75M | — | +53.9% |
| Operating income | -$32.56M | -$21.15M | -$25.20M | -$26.51M | -$41.75M | — | -53.9% |
| Net interest income | $17.00K | -$5.00K | $235.00K | $571.00K | $969.00K | — | +440.0% |
| Pre-tax income | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | — | -57.8% |
| Net income | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | — | -57.8% |
| Net income to common | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | — | -57.8% |
| Basic EPS | -0.45 | -0.33 | — | -0.44 | -0.68 | -0.48 | -36.4% |
| Diluted EPS | -0.45 | -0.33 | — | -0.44 | -0.68 | -0.48 | -36.4% |
| EBIT | -$31.62M | -$19.67M | -$24.05M | -$25.38M | -$39.90M | — | -60.8% |
| EBITDA | -$31.58M | -$19.62M | -$24.01M | -$25.34M | -$39.86M | — | -60.9% |
| Basic shares | 72.25M | 63.22M | — | 60.57M | 60.57M | 60.53M | +14.3% |
| Diluted shares | 72.25M | 63.22M | — | 60.57M | 60.57M | 60.53M | +14.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $59.44M | $51.80M | $53.99M | $46.83M | $36.81M | +14.8% |
| Cash & short-term investments | $110.20M | $128.40M | $116.86M | $126.61M | $143.37M | -14.2% |
| Total current assets | $115.51M | $133.09M | $122.25M | $132.15M | $148.40M | -13.2% |
| Property, plant & equipment | $152.00K | $197.00K | $243.00K | $288.00K | $335.00K | -22.8% |
| Goodwill & intangibles | $24.00K | $24.00K | $29.00K | $30.00K | $50.00K | 0.0% |
| Total assets | $116.01M | $133.63M | $122.83M | $142.22M | $171.90M | -13.2% |
| Total current liabilities | $46.85M | $29.23M | $30.01M | $21.96M | $24.86M | +60.3% |
| Current debt | $19.67M | $14.12M | $8.77M | $3.60M | — | +39.3% |
| Long-term debt | $11.90M | $16.92M | $22.40M | $27.05M | $29.88M | -29.7% |
| Total debt | $31.65M | $31.16M | $31.31M | $30.84M | $30.10M | +1.6% |
| Total liabilities | $58.74M | $46.15M | $52.40M | $49.05M | $54.82M | +27.3% |
| Retained earnings | -$499.92M | -$467.20M | -$446.46M | -$421.32M | -$394.87M | -7.0% |
| Shareholder equity | $57.26M | $87.48M | $70.43M | $93.17M | $117.08M | -34.5% |
| Working capital | $68.67M | $103.86M | $92.25M | $110.20M | $123.54M | -33.9% |
| Net tangible assets | $57.24M | $87.45M | $70.40M | $93.14M | $117.03M | -34.5% |
| Shares issued | 72.31M | 72.23M | 60.58M | 60.57M | 60.57M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | — | -57.8% |
| Depreciation & amortisation | $45.00K | $46.00K | $45.00K | $47.00K | $47.00K | — | -2.2% |
| Stock-based compensation | $2.52M | $2.40M | $2.42M | $2.46M | $2.50M | — | +5.3% |
| Change in working capital | $11.74M | -$5.74M | $2.99M | -$7.03M | $6.28M | — | +304.6% |
| Operating cash flow | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.83M | — | +25.1% |
| Capital expenditure | — | — | — | — | -$9.00K | -$79.00K | — |
| Investing cash flow | $26.00M | -$13.81M | $26.25M | $40.51M | $38.48M | — | +288.3% |
| Share buybacks | $0 | -$149.00K | $0 | $0 | $0 | — | +100.0% |
| Financing cash flow | -$278.00K | $35.74M | $2.00K | $0 | $0 | — | -100.8% |
| Free cash flow | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.84M | — | +25.1% |
| End cash position | $59.67M | $52.03M | $54.22M | $47.06M | $37.04M | — | +14.7% |
Options analytics
Put / call volume
0.03
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
+23.2% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
151
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
7.50
312 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.41 | -0.45 | -11.0% |
| Mar 2026 | -0.46 | -0.33 | +28.3% |
| Dec 2025 | -0.56 | -0.41 | +26.3% |
| Sep 2025 | -0.68 | -0.44 | +35.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.38 | 3 | $0 | 0.0% |
| Next quarter | -0.40 | 3 | $0 | 0.0% |
| Current year | -1.59 | 3 | $0 | 0.0% |
| Next year | -1.43 | 3 | $0 | 0.0% |
Analyst targets & ownership
Mean target$7.60
High target$10.00
Low target$5.00
Implied upside274.38%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders6.79%
Held by institutions66.59%
Institutions holding129
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.18
-6.94% from price
SMA 20
2.46
-17.47% from price
SMA 50
2.60
-22.06% from price
SMA 100
2.50
-18.64% from price
SMA 200
2.51
-19.07% from price
EMA 12
2.26
-10.02% from price
EMA 26
2.45
-17.02% from price
EMA 50
2.53
-19.68% from price
RSI (14)
31.8
Neutral
MACD (12,26,9)
-0.19
Hist -0.05
ATR (14)
0.18
8.66% of price
Realised vol 30D
71.5%
Annualised
Bollinger upper
3.06
20, 2σ
Bollinger lower
1.86
20, 2σ
50 / 200 cross
Golden
2.60 vs 2.51
Trend bias
Below 200
-19.07%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.91
More volatile than market
Correlation to SPY
0.30
Largely independent
Realised vol 30D
71.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.8%
Peak to trough
Max drawdown 5Y
-94.1%
Peak to trough
ATR 14
0.18
8.66% of price
Beta (reported)
0.33
5Y monthly, from filing
Short interest
Shares short
2.80M
Prior 3.23M
Change vs prior
-13.1%
Shorts covering
% of float
5.56%
Normal
% of shares out
3.88%
Against total outstanding
Days to cover
7.6
Crowded exit
Float
37.05M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 15, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 26, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 16, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 27, 26 | BTIG | MAINTAINED | Buy | Buy |
| Nov 18, 25 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 25, 25 | B of A Securities | MAINTAINED | Buy | Buy |
| Jun 17, 25 | Citigroup | INITIATED | — | Buy |
| Mar 28, 25 | UBS | MAINTAINED | Buy | Buy |
| Mar 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 13, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 3, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-16
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-05-12
Proxy Statements
DEFA14A · 2026-04-23
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-03-30
Offering Registrations
S-3 · 2026-03-26
Headlines
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Zacks · 16d ago
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
GlobeNewswire · 27d ago
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · 35d ago
Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...
GuruFocus.com · 55d ago
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 56d ago
Acumen Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 56d ago
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
GlobeNewswire · 56d ago
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
GlobeNewswire · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.